Document is current
Any future updates will be listed below
-
Authors
Conforti, Antonella https://orcid.org/0000-0001-8524-5936
Salvatori, Erika
Lione, Lucia
Compagnone, Mirco
Pinto, Eleonora
Shorrock, Clay
Hayward, James A.
Sun, Yuhua
Liang, Ben Minghwa
Palombo, Fabio
Viscount, Brian
Aurisicchio, Luigi
-
Funding
Funding for this research was provided by:
Ministero dello Sviluppo Economico (F/190180/01/X44)
Regione Campania (B61G18000470007)
- License Information
-
More Information
Article History
Received: 22 February 2022
Accepted: 20 May 2022
First Online: 6 June 2022
Declarations
:
: All animal experiments were performed according to the guidelines for the care and use of laboratory animals and were approved by the ethical committee of the Italian Ministry of Health, with authorization #1166/2020-PR.
: All authors have read and approved submission to this journal.
: Evvivax, Takis and NeoMatrix are currently developing proprietary nucleic-acid vaccines based on DNA-EP. Applied DNA is commercializing LinearDNA™, its proprietary, large-scale PCR-based manufacturing platform that allows for the large-scale production of specific DNA sequences. The Company’s common stock is listed on NASDAQ under ticker symbol ‘APDN,’ and its publicly traded warrants are listed on OTC under ticker symbol ‘APPDW.’
